Notably, DLBCL often harbors mutations in genes involved in immune evasion and NF-κB pathway activation, such as MYD88 and CD79B, which contribute to sustained B-cell receptor signaling and oncogenic progression [8]. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.